Charles Elliott Sigal

This profile gathers the share dealings of Charles Elliott Sigal across 4 companies, led by Vir Biotechnology, Inc., Adaptimmune Therapeutics PLC and Alnylam Pharmaceuticals, Inc. In total, 17 filings cover trades dated from 16 May 2016 to 20 May 2026.

Every open-market trade on record is a purchase: 8 purchases worth €314k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 7 share grants.

In size, the median ticket on the buying side is €37k. The 8 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The record was last updated on 22 May 2026 with a share grant in Alnylam Pharmaceuticals, Inc. The last purchase on record was published on 2 March 2023, which is 1,332 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.